Reverse transcriptase-polymerase chain reaction detection of circulating tumor cells in patients with melanoma:: Correlation with clinical stage, tumor thickness and histological type

被引:9
作者
Carrillo, E
Prados, J
Melguizo, C
Marchal, JA
Vélez, C
Serrano, S
Boulaiz, H
Mérida, JA
Aránega, A [1 ]
机构
[1] Univ Granada, Secc Invest Basica Cardiovasc, Dept Ciencias Morfol, Fac Med,Sch Med, E-18071 Granada, Spain
[2] Univ Jaen, Dept Hlth Sci, Jaen, Spain
[3] Univ Almeria, Dept Hlth Sci, Almeria, Spain
[4] Univ Granada, Sch Med, Dept Dermatol, E-18071 Granada, Spain
[5] Univ Granada, Sch Med, E-18071 Granada, Spain
关键词
circulating tumor cells; melanoma patients; metastatic disease; PCR; tyrosinase mRNA;
D O I
10.1046/j.1440-1827.2002.01344.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The aim of this study was to evaluate the correlation between the detection of circulating melanoma cells and prognostic criteria for malignant melanoma such as clinical stage, tumor thickness and histological type of the primary tumor. Using a reverse transcriptase-polymerase chain reaction (RT-PCR) technique, melanoma cells were identified by detecting tyrosinase mRNA in peripheral blood from 58 patients with malignant melanoma classified according to the American Joint Committee on Cancer guidelines. The results of the RT-PCR assay for tyrosinase were related to two prognostic markers typically used to evaluate these tumors: clinical stage and thickness. Positive PCR results were more frequent in primary tumors measuring > 4 mm (83%) than in thinner tumors (1.1-4.0 mm, 74%; less than or equal to 1.0 mm, 23%) (P = 0.005). No statistical correlation was found between the PCR results and histological appearance of the primary tumor. Although further studies are necessary, our results suggest the possible application of the PCR assay for tyrosinase mRNA in clinical evaluation of the prognosis of malignant melanoma.
引用
收藏
页码:294 / 299
页数:6
相关论文
共 32 条
[1]   POLYMERASE CHAIN-REACTION DETECTION OF CIRCULATING MELANOCYTES AS A PROGNOSTIC MARKER IN PATIENTS WITH MELANOMA [J].
BATTAYANI, Z ;
GROB, JJ ;
XERRI, L ;
NOE, C ;
ZAROUR, H ;
HOUVAENEGHEL, G ;
DELPERO, JR ;
BIRMBAUM, D ;
HASSOUN, J ;
BONERANDI, JJ .
ARCHIVES OF DERMATOLOGY, 1995, 131 (04) :443-447
[3]  
BROSSART P, 1995, CANCER RES, V55, P4065
[4]   HEMATOGENOUS SPREAD OF MALIGNANT-MELANOMA CELLS IN DIFFERENT STAGES OF DISEASE [J].
BROSSART, P ;
KEILHOLZ, U ;
WILLHAUCK, M ;
SCHEIBENBOGEN, C ;
MOHLER, T ;
HUNSTEIN, W .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 101 (06) :887-889
[5]   DETECTION OF RESIDUAL TUMOR-CELLS IN PATIENTS WITH MALIGNANT-MELANOMA RESPONDING TO IMMUNOTHERAPY [J].
BROSSART, P ;
KEILHOLZ, U ;
SCHEIBENBOGEN, C ;
MOHLER, T ;
WILLHAUCK, M ;
HUNSTEIN, W .
JOURNAL OF IMMUNOTHERAPY, 1994, 15 (01) :38-41
[6]   Polymerase chain reaction for detection of melanoma in peripheral blood: Too early to assess clinical value [J].
Buzaid, AC ;
Balch, CM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (09) :569-570
[7]  
Carrillo E, 1998, CELL MOL BIOL, V44, P1247
[8]  
CLARK WH, 1969, CANCER RES, V29, P705
[9]   Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma [J].
Curry, BJ ;
Myers, K ;
Hersey, P .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1760-1769
[10]   RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood:: Evaluation strategy and correlation with known prognostic markers in 123 melanoma patients [J].
Farthmann, B ;
Eberle, J ;
Krasagakis, K ;
Gstöttner, M ;
Wang, NP ;
Bisson, S ;
Orfanos, CE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (03) :263-267